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In this issue of Immunity, Hall et al. (2008) demonstrate that commensal bacterial DNA can suppress Treg cell
conversion via TLR9-mediated activation of lamina propria dendritic cells and thus potentially disrupt intes-
tinal homeostasis.Commensal bacteria express a range of
Toll-like receptors (TLR) and NOD-like re-
ceptor (NLR) ligands, but normally do not
induce excessive inflammation and are
not eliminated by host immune effector
mechanisms. In contrast, protective in-
nate and adaptive immune responses
are generated against pathogenic enteric
bacteria. This paradox has been ex-
plained on the basis of regulatory T
(Treg) cell-mediated tolerance to com-
mensal bacteria and preferential develop-
ment of host effector responses to patho-
genic bacteria. However, commensal
bacteria have also been implicated in
promoting inflammatory bowl disease
(Strober et al., 2007). The mechanism is
thought to involve either a breakdown of
immunological tolerance because of de-
fective mucosal Treg cells, overactive ef-
fector T cells, or differences in the compo-
sition of the gut microflora in susceptible
individuals. The paper by Hall et al.
(2008) in this issue of Immunity adds an-
other twist to this story by reporting that
activation of TLR9 on lamina propria den-
dritic cells (LpDCs) helps to promote in-
testinal inflammation by suppressing
Treg cells. The study demonstrates that
activation of TLR9 by gut flora DNA can
disrupt intestinal homeostasis, promoting
T helper 1 (Th1) and Th17 responses,
while inhibiting conversion of Treg cells,
thorough activation of LpDCs. The find-
ings support a growing number of reports
that TLR agonists can directly or indirectly
influence the induction or function of Treg
as well as effector T cells and provide ev-
idence to consolidate the proposed role
of commensal bacteria in promoting in-
testinal inflammation.
Activation of TLR and NLR signaling
pathways by pathogen-derived mole-
cules plays a major role in activating in-
nate immune responses and in host de-
fense against infection. TLR agonists518 Immunity 29, October 17, 2008 ª2008 Epromote the induction of Th1 cells, by en-
hancing DC maturation and induction of
interleukin 12 (IL-12) production. Further-
more, TLR and NLR agonists synergize
to induce the production of IL-1, IL-6,
TGF-b, and IL-23 by DCs, which drive
the differentiation and expansion of Th17
cells. It has also been demonstrated that
TLR agonists, including LPS and CpG,
can stimulate IL-10 production from DCs
and thereby promote the induction of IL-
10-producting Treg cells, simultaneously
with Th1 cells and Th17 cells (Jarnicki
et al., 2008). Finally, it has been demon-
strated that TLR agonists can induce
production of transforming growth fac-
tor-beta (TGF-b), indolamine 2,3-dioxyge-
nase, interferon-alpha (IFN-a), and
prostaglandin E2, which have been impli-
cated in peripheral conversion or expan-
sion of CD4+Foxp3+ T cells (Conroy et al.,
2008). Therefore, TLR agonist interaction
with their receptors on DCs has the ca-
pacity to induce or expand Treg, as well
as effector and pathogenic T cells. This
may reflect a protective mechanism of
the host to limit excessive inflammation
and collateral tissue damage during infec-
tion. However, the role of TLR in the in-
duction of Treg cells is still controversial,
because there is also evidence that TLR
agonists can have direct and indirect sup-
pressive effects on Treg cells, leading to
a breakdown in tolerance to self antigens
(Conroy et al., 2008). It has been reported
that TLR-induced IL-6 production by
DCs blocks the suppressive function of
CD4+CD25+ Treg cells (Pasare and Medz-
hitov, 2003). Conversely, TLR4-activated
DCs have been shown to indirectly en-
hance the suppressive function of Treg
cells through IL-1 and IL-6 production
(Kubo et al., 2004).
The paper by Hall et al. (2008) in this
issue adds further complexity by showing
that TLR9 agonists can suppress Treglsevier Inc.cell conversion in intestinal tissues
through interaction with LpDCs. The
study demonstrates that Tlr9/ mice
have enhanced CD4+FoxP3+ T cells in
the Peyer’s patches and lamina propria,
with a concomitant reduction in the fre-
quency of IFN-g- and IL-17-secreting
CD4+ T cells. They went on to demon-
strate that TLR9 signaling had a more pro-
found effect on the balance of effector to
regulatory T cells in the gut than in the pe-
riphery. Antigen-specific Th1 responses
induced in response to the intracellular
parasite Encephalitozoon cuniculi were
similar in Tlr9/ and WT mice infected
intraperitoneally, but Th1 and Th17 re-
sponses and parasite clearance was sub-
stantially reduced in Tlr9/ mice infected
by the oral route. Furthermore, intestinal
effector T cell responses induced by
oral immunization with a model antigen
and mucosal adjuvant were reduced in
Tlr9/ mice.
Belkaid and colleagues had previously
shown that oral exposure to antigen can
induce conversion of CD4+Foxp3
T cells to CD4+Foxp3+ T cells, mediated
by LpDCs, via TGF-b and retinoic acid.
Consequently, in the current manuscript
they examined the influence of commen-
sal bacterial DNA on Treg cell activation.
LpDCs stimulated with CpG (a TLR9 ago-
nist), but not by TLR2, TLR4, or TLR5
agonists, suppressed conversion of Treg
cells (Hall et al., 2008). This was accom-
panied by enhancement of Th1 and
Th17 cells by CpG-activated LpDCs. The
IL-17 induction was explained on the ba-
sis of IL-6 production by the CpG-acti-
vated LpDCs, because anti-IL-6 blocked
Th17 activation. However, they did not
examine IL-1, TGF-b, or IL-23, which
have also been shown to be required for
induction and expansion of Th17 cells.
Furthermore, they did not provide a defin-
itive mechanism to explain suppression of
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PreviewsFigure 1. Gut Flora DNA Can Disrupt Intestinal Homeostasis
In steady-state conditions, intestinal homeostasis is maintained through Treg cell suppression of effector T cells, and lamina propria dendritic cells (LpDCs) play
a role by enhancing conversion of CD4+Foxp3 to CD4+Foxp3+ Treg cells, through retinoic acid (RA) and TGF-b. However, in susceptible individuals (e.g., with
polymorphisms in key innate receptors or with altered gut microflora composition), LpDCs, which can sample bacteria across the intestinal epithelium, are likely
activated by the commensal bacterial DNA through TLR9. After TLR9 activation, the LpDCs secrete IL-6 and probably other cytokines that promote differentiation
and expansion of Th17 and Th1 cells. In addition, the TLR9-activated LpDCs suppress Treg conversion, through negative feedback by Th1-derived IFN-g,
in combination with IL-4 and IL-6. Thus, TLR9-activated LpDCs can alter the balance of effector over regulatory T cells and thereby promote intestinal
inflammation.Treg by TLR9-activated LpDCs. There
was evidence to suggest that this may in
part be mediated by IL-4, IFN-g, and IL-6,
but the cellular source of the suppressive
cytokines was not clear.
Having shown that CpG can block Treg
conversion by interacting with TLR9 on
LpDCs, Hall et al. (2008) demonstrated
that DNA enriched from gut flora could
mediate the same effect. Furthermore,
gut flora DNA was capable of replacing
commensal bacteria (removed with anti-
biotics) in inducing effector Th1 and
Th17 responses and clearance of E. cuni-
culi. These findings support the hypothe-
sis that commensal bacteria may in
some cases help to dysregulate the bal-
ance of intestinal effector over regulatory
T cells, leading to intestinal inflammation
(Figure 1). However, the study also poses
a number of questions. First, what is so
special about TLR9? TLR2, TLR4, and
TLR5 are expressed on LpDCs or epithe-
lial cells in the gut, and agonists for these
receptors are also produced by gut mi-
croflora, so why do they not also inhibit
Treg cells? Second, why LpDCs and
why do they behave differently from DCs
in other lymphoid tissues? Finally, if com-
mensal bacteria are able to suppress Treg
responses allowing uncontrolled inflam-
mation, why do we all not get colitis?
Clearly, genetic and environmental fac-tors have a major role in determining sus-
ceptibility to intestinal inflammation. Indi-
viduals with polymorphisms in NOD2
gene have increased susceptibility to
Crohn’s disease (CD) and there is also
evidence that CD is associated with poly-
morphisms in TLRs, including TLR9. Al-
though NOD2 and TLR9 agonists can
synergize to activate innate inflammatory
cytokines that promote Th1 and Th17 re-
sponses, it has been suggested that
NOD2 activation has a protective role
against intestinal inflammation, in part by
inhibiting TLR signaling pathways
(Strober et al., 2007).
The findings by Hall et al. (2008) that
TLR9 activation by gut microflora DNA en-
hances inflammation are backed by re-
ports that enteric bacteria are necessary
for the development of spontaneous coli-
tis and that TLR9 agonists can overcome
tolerance and precipitate autoimmune
diseases in mouse models. However,
other investigators have suggested that
commensal bacteria and TLR agonists
can protect against intestinal inflamma-
tion. A study showing that DSS-induced
colitis is more severe in Myd88/ mice
suggested that TLR activation by com-
mensal bacteria plays a role in the mainte-
nance of intestinal homeostasis (Rakoff-
Nahoum et al., 2004). It was also reported
that commensal bacteria may reduce theImmunity 29frequency of Th17 cells in the intestine;
germ-free mice had enhanced IL-23, IL-
12, and IL-17, and commensal induction
of IL-25 in conventional mice regulated
IL-23-induced IL-17 production (Zaph
et al., 2008). Furthermore, s.c. administra-
tion of TLR9 agonists have been shown to
protect mice from colitis through IFN-a
production (Katakura et al., 2005).
The difference between studies sug-
gesting positive and negative roles for
TLRs in Treg cell responses may in part
reflect the different experimental sys-
tems, cell types, and tissues examined.
The study by Hall et al. (2008) demon-
strates functional differences between
LpDCs and splenic DCs and between
oral and parental routes of antigen expo-
sure, suggesting that there may be intrin-
sic difference between DCs in intestinal
and secondary lymphoid tissues. The
recent paper by Goubier et al. (2008)
demonstrating that oral tolerance is
mediated by plasmacytoid DCs in the
liver provides further evidence that tis-
sue-specific DCs may have distinct func-
tions and that different DC subtypes
may mediate tolerance versus effector
immune responses.
If the findings in mice (that gut flora DNA
enhances rather than inhibits intestinal
inflammation) translates to humans, then
inhibition of TLR9 signaling may be, October 17, 2008 ª2008 Elsevier Inc. 519
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ment of new therapeutic interventions
against CD, especially if they can be se-
lectively targeted to the gut or lamina
propria. Furthermore, the findings might
also help to tackle a long-standing prob-
lem in the vaccine field. Oral vaccines
have considerable attractions in terms of
ease of administration but are constrained
by poor immunogenicity and induction of
tolerance by antigens delivered by this
route. Suppression of Treg cell induction
has been shown to enhance the efficacy
of vaccines delivered by parenteral routes
(Jarnicki et al., 2008). Therefore, suppres-
sion of Treg cell conversion by commen-
sal DNA or synthetic TLR9 agonists has
potential to reverse tolerance and
improve the immunogenicity of vaccines
delivered by the oral route.CMV and the Art o
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The CD8+ T cell responses to CMV g
In this issue of Immunity, Snyder et
continuous turnover of inflating T ce
Cytomegaloviruses are ubiquitous patho-
gens. Human CMV (HCMV) infects most
of the human population, usually asymp-
tomatically, and persists lifelong. The
cellular immune responses to HCMV are
vigorous and sustained—indeed they
tend to increase over time and may
come to dominate the peripheral blood
of healthy elderly donors (Khan et al.,
2002). They are also essential for viral
control, given that immunosuppression
for transplantation or as a result of human
immunodeficiency virus (HIV) infection
can lead to viral reactivation and severe
disease.
This host-virus balance has been stud-
ied by Snyder and colleagues (Snyder
et al., 2008, this issue of Immunity) with
the murine (MCMV) model, in which
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CMVs are large viruses, with a number
of open reading frames, but memory infla-
tion is only seen for a small subset of
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work by the group of Hill, preceding the
study of Snyder in this issue, has shown
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